



Capastat[®] Sulfate (capreomycin) – Drug shortage

- The [drug shortage](#) of Akorn's [Capastat Sulfate \(capreomycin\)](#) injection is ongoing. Capastat has been unavailable for at least 90 days due to a delay in shipping of the drug. Akorn estimates that product will be available in the fourth quarter of this year.
- Capastat, which is to be used concomitantly with other appropriate antituberculosis agents, is indicated in pulmonary infections caused by capreomycin-susceptible strains of *Mycobacterium tuberculosis* when the primary agents ([isoniazid](#), [rifampin](#), [ethambutol](#), [Paser[®]](#) [[aminosalicylic acid](#)], and [streptomycin](#)) have been ineffective or cannot be used because of toxicity or the presence of resistant tubercle bacilli.

Product Description	NDC #
Capastat sulfate (capreomycin) for injection, 1 g, 10 mL vial	17478-080-50



OptumRx[®] specializes in the delivery, clinical management and affordability of prescription medications and consumer health products. We are an Optum[®] company — a leading provider of integrated health services. Learn more at [optum.com](#).

All Optum[®] trademarks and logos are owned by Optum, Inc. All other brand or product names are trademarks or registered marks of their respective owners.

This document contains information that is considered proprietary to OptumRx and should not be reproduced without the express written consent of OptumRx.

RxNews[®] is published by the OptumRx Clinical Services Department.

©2019 Optum, Inc. All rights reserved.